Cmv |
|
|
Clinical Trial: CMV-Ig Replacement in Hypogammaglobulinemic Lung Transplant Recipients
This study is no longer recruiting patients.
|
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Lung Transplantation Hypogammaglobulinemia | Drug: CMV-Ig | Phase II Phase III |
MedlinePlus related topics: Blood and Blood Disorders; Immune System and Disorders; Lymphatic Diseases
Study Type: Interventional
Study Design: Prevention, Randomized, Open Label, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Does Replacement with CMVIG in Hypogammaglobulinemic Patients Decrease the Rate of Opportunistic Infections and Chronic Rejection?
Secondary Outcomes: Chronic Rejection
Expected Total Enrollment: 50
Study start: January 2001
Last follow-up: January 2006
Eligibility
Inclusion Criteria:
- lung transplant hypogammaglobulinemia
Exclusion Criteria:
-
Location Information
Ohio
Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States
Jeff T Chapman, MD, Principal Investigator, Cleveland Clinic Foundation
More Information
Last Updated: August 29, 2005
Record first received: August 29, 2005
ClinicalTrials.gov Identifier: NCT00137748
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13

Not Signed In -


